AmericanPharmaceuticalPartners(Schaumburg,Ill) recently receivedFDA approvalfor its abbreviatednew drug applicationfor Azithromycin forInjection. The product is the genericequivalent of Pfizer Inc's Zithromax.Azithromycin for Injection is indicated forthe treatment of community-acquiredpneumonia and pelvic inflammatory disease,when caused by susceptiblemicroorganisms. The product will beavailable in 500-mg vials. Azithromycinfor Injection is preservative-free, andeach vial will include a bar code andlatex-free vial stopper. For more information,visit www.appdrugs.com.